Natraj Proteins Ltd Upgraded to Sell on Technical Improvements and Valuation Appeal

Quality Assessment: Persistent Fundamental Weakness

Despite the recent upgrade, Natraj Proteins’ quality grade remains subdued, reflecting its ongoing struggles with long-term fundamentals. The company has recorded a negative compound annual growth rate (CAGR) of -5.06% in net sales over the past five years, signalling a contraction in its core revenue base. This decline is compounded by a modest average Return on Equity (ROE) of 6.97%, indicating limited profitability relative to shareholders’ funds. Such figures suggest that the company has yet to establish a robust and sustainable earnings profile.

Moreover, Natraj Proteins has consistently underperformed its benchmark indices, including the BSE500, over the last three years. The stock’s one-year return stands at -22.68%, starkly contrasting with the Sensex’s positive 5.52% return over the same period. Over a three-year horizon, the stock has declined by nearly 33%, while the Sensex has surged by over 32%. This persistent underperformance highlights structural challenges within the company’s operational and market positioning.

Valuation: Attractive Yet Reflective of Risks

On the valuation front, Natraj Proteins presents an intriguing case. The company’s Return on Capital Employed (ROCE) is reported at 1%, which, while low, is accompanied by an enterprise value to capital employed ratio of just 0.6. This suggests that the stock is trading at a significant discount relative to its capital base and peers’ historical valuations. The price-to-earnings-to-growth (PEG) ratio of 0.1 further underscores the market’s cautious stance, implying that the stock is undervalued relative to its earnings growth potential.

However, this valuation attractiveness is tempered by the company’s weak long-term growth trajectory and profitability metrics. Investors should weigh the discounted price against the risks posed by the company’s operational challenges and competitive pressures within the edible oil sector.

Financial Trend: Signs of Recovery in Recent Quarters

Financially, Natraj Proteins has demonstrated encouraging signs in the latest quarterly results for Q3 FY25-26. After two consecutive quarters of negative performance, the company reported a positive turnaround with a Profit After Tax (PAT) of ₹1.24 crore over the last six months, representing a remarkable growth of 226.53%. Operating profit margins have also improved, with PBDIT reaching a quarterly high of ₹3.54 crore and operating profit to net sales ratio peaking at 12.30%.

These improvements indicate that the company may be stabilising its operations and improving cost efficiencies. However, the broader financial trend remains mixed, as the stock’s year-to-date return is still negative at -1.56%, and the five-year CAGR in net sales remains in decline. Investors should monitor upcoming quarters closely to confirm whether this recovery is sustainable.

Technical Analysis: Shift from Bearish to Mildly Bearish Signals

The primary catalyst for the upgrade in Natraj Proteins’ investment rating is the improvement in its technical grade, which moved from bearish to mildly bearish as of early March 2026. This shift is supported by a mixed but cautiously optimistic set of technical indicators across multiple timeframes.

On a weekly basis, the Moving Average Convergence Divergence (MACD) indicator has turned mildly bullish, signalling a potential positive momentum shift. Similarly, the Know Sure Thing (KST) oscillator on the weekly chart also reflects mild bullishness. However, monthly MACD and KST remain bearish, indicating that longer-term trends have yet to confirm a sustained uptrend.

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, suggesting a neutral momentum stance. Bollinger Bands indicate mild bearishness on the weekly timeframe and bearishness monthly, while daily moving averages remain mildly bearish. Dow Theory analysis shows a mildly bearish trend weekly and no clear trend monthly.

Price action has been volatile but positive in the short term, with the stock closing at ₹31.50 on 11 March 2026, up 6.56% from the previous close of ₹29.56. The stock’s intraday high reached ₹34.90, while the 52-week low and high stand at ₹28.00 and ₹47.90 respectively. This technical improvement has contributed significantly to the upgrade in the Mojo Grade from Strong Sell to Sell, reflecting a cautious but more optimistic market sentiment.

Comparative Performance: Lagging Behind Benchmarks

Despite recent technical gains, Natraj Proteins continues to lag behind key market benchmarks over most time horizons. The stock outperformed the Sensex only in the one-week period, delivering a 7.22% return compared to the Sensex’s -2.53%. However, over one month, year-to-date, one year, three years, and five years, the stock has underperformed the benchmark indices significantly.

For instance, over the last three years, the stock has declined by 32.98%, while the Sensex has appreciated by 32.25%. Over ten years, the stock’s return of 8.43% pales in comparison to the Sensex’s 217.61% gain. This persistent underperformance highlights the challenges faced by Natraj Proteins in delivering shareholder value relative to broader market opportunities.

Shareholding and Market Position

Natraj Proteins’ majority shareholding is held by non-institutional investors, which may contribute to higher volatility and less predictable trading patterns. The company operates within the refined oil and vanaspati segment of the edible oil industry, a sector characterised by intense competition and fluctuating commodity prices. These factors, combined with the company’s modest financial metrics, suggest that investors should remain cautious despite recent technical improvements.

Conclusion: A Cautious Upgrade Reflecting Technical Recovery

The upgrade of Natraj Proteins Ltd’s investment rating from Strong Sell to Sell reflects a nuanced assessment of its current position. While the company’s fundamental quality and long-term financial trends remain weak, recent quarterly results and technical indicators have shown signs of improvement. The stock’s valuation appears attractive relative to its capital employed and earnings growth, but this is offset by persistent underperformance against benchmarks and low profitability metrics.

Investors considering Natraj Proteins should weigh the potential for a technical rebound against the risks posed by its structural challenges. Continued monitoring of quarterly financial performance and technical signals will be essential to assess whether the company can sustain its recovery and improve shareholder returns over the medium term.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today